Iovance Biotherapeutics, Inc.
999 Skyway Road
Suite 150
San Carlos
California
94070
United States
Tel: 650-260-7120
Website: http://www.iovance.com/
Email: Gen_Inq_Web@iovance.com
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. After infusion, TIL reach tumor tissue, where they attack tumor cells. The company has completed dosing in the pivotal study in patients with metastatic melanoma and is currently conducting a pivotal study in patients with advanced cervical cancer. In addition, the company’s TIL therapy is being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including head and neck and non-small cell lung cancer. A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy is open to enrollment.
HEADQUARTERS
999 Skyway Road
Suite 150
San Carlos, CA 94070
Phone: 650-260-7120
PHILADELPHIA
300 Rouse Blvd Navy Yard Corporate Center
Philadelphia, PA 19112
Stock Symbol: IOVA
190 articles with Iovance Biotherapeutics, Inc.
-
Iovance Biotherapeutics to Present at Upcoming Conferences in December
11/30/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in November: Piper Sandler 32nd Annual Virtual Healthcare Conference | December 1-3, 2020 Date/Time: presentation available at http://ir.iovance.com Cellular Immunotherapies for Solid Tumors Summit | December 1-
-
Iovance Biotherapeutics Presents Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
11/9/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today presented new interim clinical data for the tumor infiltrating lymphocyte (TIL) therapy LN-145
-
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2020 Financial Results and Corporate UpdatesRegistration-Directed Study Initiated in Non-Small Cell Lung Cancer
11/5/2020
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported third quarter 2020 financial results and provided a corporate update.
-
Iovance Biotherapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5, 2020
10/30/2020
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter 2020 financial results on Thursday, Nov. 5, 2020.
-
Iovance Biotherapeutics to Present at Upcoming Conferences in November
10/28/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences in November: Next Generation CAR and T Cell Therapies Conference (Virtual) | Nov . 2-5, 2020 Date/Time: Monday, Nov. 2 at 5:20 p.m. EST Credit Suisse 29th Annual Virtual Healthcare Conference | Nov . 9-12, 2
-
Iovance Biotherapeutics to Present Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
10/14/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), today announced that new interim clinical data for the tumor infiltrating lymphocyte (TIL) therapy LN-145 in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC) will be presented at the 35th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
-
Iovance Biotherapeutics to Present at Upcoming October 2020 Conferences
10/6/2020
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that the company plans to present at the following conferences.
-
Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma
10/5/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today provided a regulatory update for its tumor-infiltrating lymphocyte (TIL) therapy lifileucel in metastatic melanoma
-
Iovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020
8/7/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the BTIG Biotechnology Conference 2020 (Virtual) on August 11, 2020 at 2:30pm ET. A live and archived webcast of the presentation will be available in the Investors section of the Iovance website at http://ir.iovance.com . About Iovance Biotherapeut
-
Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate UpdateEnrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer Study
8/6/2020
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported second quarter 2020 financial results and provided a corporate update.
-
Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001
8/6/2020
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Iovance Biotherapeutics (NASDAQ: IOVA) has selected Avid to provide process development, pilot-batch manufacturing and CGMP manufacturing services t
-
Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020
7/23/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter 2020 financial results on Thursday, August 6, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EDT. To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-24
-
Iovance Biotherapeutics to Present at Upcoming June Conferences
6/8/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following virtual conferences in June
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
DLA Piper advises Iovance Biotherapeutics in its US$604 million common stock offering
6/4/2020
DLA Piper represented Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), in a US$603.7 million underwritten public offering of 19,475,806 shares of its common stock at a public offering price of $31.00 per share,
-
Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public OfferingOffering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 2.5 Million Shares of Common Stock
6/2/2020
Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the closing of an underwritten public offering of 19,475,806 shares of its common stock at a public offering price of $31.00 per share.
-
Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program
5/29/2020
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up 36.4% Overall Response Rate (ORR) Maintained SAN CARLOS, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today presented long-term interim data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma during an oral session at the American Society of Clinical Oncology’
-
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock
5/29/2020
Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the pricing of an underwritten public offering of 16,935,484 shares of its common stock at a public offering price of $31.00 per share
-
Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma
5/27/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced initial data from pivotal Cohort 4 and updated long-term data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma.
-
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
5/27/2020
Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today announced that it intends to offer and sell $500 million of its common stock, subject to market and other conditions, in an underwritten public offering.